Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Effectiveness and Tolerability of Eptinezumab: a Prospective, Multicentric, Cohort Study

ID
Name
RICe_5
Description
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
Trial arms
Trial start
2024-03-26
Estimated PCD
2025-04-01
Trial end
2026-04-01
Status
Recruiting
Treatment
Eptinezumab 100 or 300 mg ev
Patients administered eptinezumab 100 or 300 mg ev quarterly for migraine prevention
Arms:
Chronic migraine, Episodic migraine
Other names:
Eptinezumab
Size
100
Primary endpoint
Changes in migraine frequency after three months of treatment
Baseline (T0) - 3 months of treatment with eptinezumab (T3)
Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) after three months of treatment
Baseline (T0) - 3 months of treatment with eptinezumab (T3)
Eligibility criteria
Inclusion Criteria: * Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III); * Good compliance to study procedures; * Availability of headache diary at least of the preceding months before enrolment; * At least 8 monthly migraine days. Exclusion Criteria: * Subjects with contraindications for use of eptinezumab; * Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments; * medical comorbidities that could interfere with study results; * Pregnancy and breastfeeding * Changes in preventive treatments in the month before the first administration of eptinezumab
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_ONLY', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2024-05-10

1 organization

1 product

3 indications

Organization
University of Florence
Product
Eptinezumab
Indication
Migraine
Indication
Migraine With Aura
Indication
Migraine Without Aura